Enbrel

Enbrel is a medicine that contains the active substance etanercept. It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection.

Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat.

Enbrel is given by injection under the skin. For adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week. Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis. For patients below 18 years of age, the dose depends on body weight. The patient or carer can give the injection if they have been trained appropriately. For more information, see the package leaflet.

Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine.

The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF). This messenger is found at high levels in patients with the diseases that Enbrel is used to treat. By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases. Etanercept is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA) that makes them able to produce etanercept.

Overall, in the studies of rheumatoid arthritis, about two thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months. This compared with around a quarter of the patients receiving placebo. In the study of patients who had not taken methotrexate before, those receiving 25 mg Enbrel twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months. In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone.

For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo after three to four months.

The long term safety studies found that Enbrel could be used in polyarticular juvenile idiopathic arthritis in children from the age of two years and plaque psoriasis from the age of six years.

A risk management plan has been developed to ensure that Enbrel is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Enbrel, including the appropriate precautions to be followed by healthcare professionals and patients.

The company that makes Enbrel will provide educational material for doctors expected to prescribe the product (to teach patients how to use the pre-filled pen correctly) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor).

The European Commission granted a marketing authorisation valid throughout the European Union for Enbrel on 3 February 2000.

For more information about treatment with Enbrel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

The CHMP decided that Enbrel’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Enbrel is an anti-inflammatory medicine. It is used for the treatment of the following diseases:

• moderate to severe rheumatoid arthritis (an immune-system disease causing inflammation of the joints) in adults (aged 18 years or over). Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient. Enbrel can also be used in patients with severe rheumatoid arthritis who have not taken methotrexate before;
• certain forms of juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in the following groups:
  • patients aged two to 17 years who have polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate;
  • adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate;
  • adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment;
• psoriatic arthritis in adults who have not responded adequately to other treatments;
• severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments;
• plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in patients from the age of six years with long-term severe disease. Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease.
• Severe non-radiographic axial spondyloarthritis (a chronic inflammatory disease of the spine) when there are objective signs of inflammation but no abnormalities seen on x-ray.

For more information, see the summary of product characteristics (also part of the EPAR).

The medicine can only be obtained with a prescription.

Enbrel has been studied in five main studies in rheumatoid arthritis, involving about 2,200 patients and lasting from three months to two years. Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken arthritis medicines in the past. One of these studies examined Enbrel’s effects as an add-on to methotrexate in 89 patients. In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before. The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients.

Enbrel was also compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, 1,263 adults and 211 children with plaque psoriasis, as well as in 225 patients with non-radiographic axial spondyloarthritis. In all of the studies, the main measure of effectiveness was the change in symptoms.

The studies in children with polyarticular juvenile idiopathic arthritis and plaque psoriasis were followed up with long-term studies to assess the safety of long-term treatment in children.

The most common side effects with Enbrel (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections). Patients developing a serious infection should stop Enbrel treatment. For the full list of all side effects reported with Enbrel, see the package leaflet.

Enbrel must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections.

For the full list of restrictions, see the package leaflet.